Atypical patterns of response in patients (pts) with metastatic melanoma treated with pembrolizumab (MK-3475) in KEYNOTE-001.
Jedd D. Wolchok(Cornell University), F. Stephen Hodi(Harvard University), Andrea Perrone(Università Cattolica del Sacro Cuore), Hassane M. Zarour(University of Pittsburgh), Roxana Dronca(Dana-Farber Cancer Institute), Omid Hamid(Cedars-Sinai Medical Center), Richard W. Joseph(Daiichi Sankyo (United States)), Jeffrey S. Weber(NYU Langone Health), Richard Kefford(Broad Institute), Amita Patnaik(South Texas Accelerated Research Therapeutics), Antoni Ribas(University of California, Los Angeles), Anthony M. Joshua(St Vincent's Hospital Sydney), Caroline Robert(Institut Gustave Roussy), Xiaoyun Li(Nanjing University), Wen‐Jen Hwu(The University of Texas MD Anderson Cancer Center), Tara C. Gangadhar(University of Pennsylvania), Soonmo Peter Kang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States)), Dahai Xue(Dana-Farber Cancer Institute), Adil Daud(University of California, San Francisco)
Cited by 20
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k